Sab Biotherapeutics, INC

SAB Biotherapeutics announced a grant from Breakthrough T1D to support a clinical study evaluating SAB-142 in patients with Stage 3 Type 1 Diabetes.

SAB Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of four Class II directors and the ratification of its independent auditor.

SAB Biotherapeutics has entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for its SAB-142 product.

SAB Biotherapeutics announced positive Phase 1 trial data for SAB-142, showing C-peptide preservation and improved glycemic control in Type 1 Diabetes patients.

SAB Biotherapeutics provides a corporate update, highlighting positive Phase 1 data for SAB-142, initiation of its registrational Phase 2b SAFEGUARD study, and a cash runway through 2028.

SAB Biotherapeutics appoints Dr. David Zaccardelli as Board Chair and Dr. Rita Jain as an independent director, enhancing leadership for clinical development.

SAB Biotherapeutics, Inc. reported a net loss of $22.5 million for the second quarter of 2026, with operating expenses nearly tripling year-over-year, driven by increased clinical trial costs for its lead candidate SAB-142.

SAB Biotherapeutics details significant R&D investment and progress in its lead Type 1 Diabetes therapy, SAB-142, alongside a substantial capital raise.

SAB Biotherapeutics reported a significant financial turnaround in Q3 2025, driven by a $175 million capital raise and reclassification of warrants, while advancing its lead T1D candidate, SAB-142, into Phase 2b.

SAB Biotherapeutics reported increased net losses and no revenue for Q2 2025, but secured $175 million in gross proceeds from a Series B private placement to fund its lead T1D candidate's Phase 2b study.

SAB Biotherapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash and investments.

SAB Biotherapeutics reported its Q3 2024 financial results, highlighting progress in its SAB-142 clinical trial for Type 1 Diabetes and ongoing financial challenges.

SAB Biotherapeutics announces positive Phase 1 clinical results for SAB-142, a potential disease-modifying therapy for Type 1 Diabetes, and plans to advance to a Phase 2b trial in 2025.

SAB Biotherapeutics details its registered securities, including common stock and warrants, and provides an overview of its clinical-stage pipeline in its latest 10-K filing.

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc., reported a transaction involving the withholding of shares for tax purposes.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, disposed of 988 common shares to cover tax obligations related to RSU vesting.

SAB Biotherapeutics' President and Director, Eddie Joe Sullivan, was granted 3 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics CEO Samuel J. Reich was granted 4.8 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics' Chief Operating Officer, Christoph Bausch, was granted 1.8 million stock options with an exercise price of $4.45, vesting over four years.

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, was granted 2.4 million stock options with an exercise price of $4.45 per share.

SAB Biotherapeutics, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 18, 2026.

SAB Biotherapeutics calls a special meeting to approve the conversion of Series B Preferred Stock and an expanded equity plan, potentially leading to over 2,500% common stock dilution.

SAB Biotherapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on July 17, 2025, where shareholders will vote on the election of four Class I directors and the ratification of EisnerAmper LLP as the independent registered public accounting firm, following a prior auditor's 'going concern' note and financial restatement.

SAB Biotherapeutics is holding its 2024 Annual Meeting of Stockholders virtually on June 27, 2024, to vote on key proposals including the election of directors and an amendment to the company's equity incentive plan.

RA Capital Management and its affiliates have updated their Schedule 13D filing to reflect a change in their beneficial ownership percentage of SAB Biotherapeutics, Inc. due to an increase in the issuer's outstanding common stock.

RA Capital Management and its affiliates increased their beneficial ownership in SAB Biotherapeutics, Inc. to 9.9% through the acquisition of pre-funded warrants.

RA Capital Management, L.P. and its affiliates have acquired 9.9% of SAB Biotherapeutics' common stock following a private placement and preferred stock conversion.

Caligan Partners LP and David Johnson have reported beneficial ownership of 7,967,207 shares, representing 8.8% of SAB Biotherapeutics, Inc. common stock.

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed beneficial ownership of 9.99% of SAB Biotherapeutics, Inc. common stock, including convertible securities and warrants.

Woodline Partners LP has filed a Schedule 13G, revealing beneficial ownership of 6.8% of SAB Biotherapeutics, Inc. common stock, including shares issuable from warrants and preferred stock.

Balyasny Asset Management L.P. and affiliated entities have reported an adjustment in their beneficial ownership of SAB Biotherapeutics, Inc. common stock, now holding 9.45%.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has reported beneficial ownership of 6,405,553 shares, representing 8.38% of SAB Biotherapeutics, Inc.'s common stock as of June 30, 2026.

Caligan Partners LP and David Johnson have reported beneficial ownership of 10.4% of SAB Biotherapeutics, Inc. common stock as of March 31, 2026.